Consistent with clinical observations, single-agent anti-PD-1 did not inhibit EGFRΔ19 tumor growth not only in the poorly immunogenic LLC tumor model but also in the properly immunogenic SJT1601 tumor model (Fig. 4B–D and Fig. S7A–C). The gene discussed is PDCD1; the disease is neoplasm.